Irinotecan hcl trihydrate

HPNE, HPNE EtOH, and HPNE-KRAS cells were plated at a density of 5000 cells per well in a 96-well plate. HPNE-KRAS EtOH cells were plated at 1000 cells per well (due to the high proliferation rate, the wells were 100% confluent by day 2, plated at 5000 cells per well, and complicated cell viability measurements). Cells were allowed to adhere overnight, and the drug was added at 24 h. Plates were incubated at 37 °C, 5% CO₂ for 3 days. Cell viability was measured by CellTiter-Glo 2.0 (Promega, Madison, WI, USA, G9242), as indicated by the instruction manual. Luminescence was read by the FLUOstar Optima (BMG biotech). Gemcitabine (cat#: S1714), Irinotecan HCl Trihydrate (cat#: S2217), and Oxaliplatin (cat#: S1224) were purchased from Selleckchem (Houston, TX, USA).

All commercially available reagents were used without further purifications unless otherwise indicated. BCI-121 (SML1817), oxaliplatin (O9512), paclitaxel (T1912), 5-fluorouracil (F6627), doxorubicin (D1515), irinotecan (S-I1406), and azoxymethane (A5486) were purchased from Sigma-Aldrich Merck. KU60019 (S1570) and irinotecan HCl trihydrate used for animal studies (S2217) were purchased from SelleckChem. Dextran sodium sulfate (160110) was purchased from MP Biomedicals. EM127 was obtained through the straightforward procedure described in Parenti et al. [22 (link)]. For nanoparticle formulation, human serum albumin (HSA) (A1653) and α-tocopherol (T3251) were purchased from Sigma-Aldrich Merck. The hydrodynamic diameter and polydispersity index (PDI) of nanoparticles in aqueous solution were determined by DLS analysis at 25 °C using a NanoBrook Omni Particle Size Analyzer (Brookhaven Instruments Corporation) equipped with a 35 mW red diode laser (nominal wavelength 640 nm). Electrophoretic mobility, i.e., ζ-potential, was measured at 25 °C using the same instrument.
For each chemical, doses and treatment duration are indicated in the Figure legends.